Previous close | 1.3500 |
Open | 1.1000 |
Bid | 1.0000 |
Ask | 1.3000 |
Strike | 30.00 |
Expiry date | 2024-08-16 |
Day's range | 1.1000 - 1.1000 |
Contract range | N/A |
Volume | |
Open interest | 522 |
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities;
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.02% and 4.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.